Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone
Nexentis Technologies, through its subsidiary MitoCareX Bio, has achieved a significant drug discovery milestone by optimizing a hit molecule targeting mitochondrial SLC25 carrier proteins, which are involved in difficult-to-treat cancers and inflammatory metabolic diseases. The milestone validates the MITOLINE® platform's capability to overcome st…